Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
This study has been completed.
Information provided by (Responsible Party):
Department of Veterans Affairs
First received: May 6, 2008
Last updated: February 20, 2015
Last verified: February 2015
Qualitative pilot study of patients' views of their experience with antiviral treatment for hepatitis C.
||Time Perspective: Retrospective
||Patients' View of Hepatitis C Treatment Completion or Withdrawal
Primary Outcome Measures:
- Attributes of Treatment Experience [ Time Frame: Zero to five years since ending treatment. ] [ Designated as safety issue: No ]
Four basic reasons for persisting in antiviral treatment were identified: cure the disease, concern about diminishing time to act (avoid bad end), demonstation of personal strength, and redemption for past behavior.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2008 (Final data collection date for primary outcome measure)
Hepatitis C patients
patients who initiated antiviral treatment for hepatitis C
Qualitative pilot study of patient' views of their experiences with antiviral treatment for hepatitis C. Two groups of patients will be sampled: nine who completed a 24 or 48 week course of treatment and nine who withdrew from treatment prior to planned end. Interview data will be analyzed using narrative and grounded theory methods to identify attributes of treatment experience that may discriminate between completion and withdrawal.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
VHA patients who ever initiated antiviral treatment for hepatitis C.
Ever initiated anitiviral treatment for hepatitis C.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00674492
|VA New England Health Care System
|Bedford, Massachusetts, United States, 01730 |
||Jack A Clark, PhD
||VA New England Health Care System
No publications provided
||Department of Veterans Affairs
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 6, 2008
|Results First Received:
||February 5, 2015
||February 20, 2015
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 26, 2015
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections